Alopexx Signs an Exclusive License Agreement with Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia

Alopexx Signs an Exclusive License Agreement with Beijing Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia

Shots:

  • Alopexx to receive up front, development & commercialization milestones along with royalties on sales. Beijing Shenogen Pharma get an exclusive license to develop & commercialize DI-Leu16-IL2 in China and other parts of Asia
  • The therapy is evaluated in P-I study assessing DI-LEU16-IL2 in 18 patients with r/r B-cell CD20+ lymphoma who received 2 or more cycles of therapy had tumor regression or stabilization including 3 complete and 2 partial responses
  • DI-LEU16-IL2 is a novel immune-cytokine targeting CD20, developed by Merck KGaA and licensed to Provenance in 2009. Later in 2011, Provenance rights to develop & commercialize the therapy to Alopexx

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Alopexx